Twist Bioscience Expects FY24 Revenue Of $285M-$290M Vs. Consensus Of $298.79M; Gross Margin Of Approximately 39%-40%
Portfolio Pulse from Benzinga Newsdesk
Twist Bioscience forecasts FY24 revenue to be between $285M-$290M, which is below the consensus estimate of $298.79M. The company also anticipates a gross margin of approximately 39%-40% for the same period.
November 17, 2023 | 12:36 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Twist Bioscience's revenue forecast for FY24 is lower than market expectations, which could lead to negative investor sentiment and a potential decrease in stock price in the short term.
Revenue forecasts that are below consensus estimates typically result in negative market reactions as they suggest a company's performance may not meet investor expectations. This can lead to a decrease in stock price as investors adjust their valuation models based on the new information. The expected gross margin aligns with industry standards and may not significantly impact the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100